Live Breaking News & Updates on Prnewswire Heron Therapeutics Inc|Page 8

Stay updated with breaking news from Prnewswire heron therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Heron Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

/PRNewswire/ Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing. ....

David Szekeres , Exchange Commission , Prnewswire Heron Therapeutics Inc , Heron Therapeutics Inc , Investor Relations , Heron Therapeutics , Private Securities Litigation Reform Act , Media Contact , Vice President , Chief Operating , Health Care Amp Hospitals , Medical Pharmaceuticals , Biotechnology , Conference Call Announcements ,

Heron Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

/PRNewswire/ Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing. ....

David Szekeres , Exchange Commission , Prnewswire Heron Therapeutics Inc , Heron Therapeutics Inc , Investor Relations , Heron Therapeutics , Private Securities Litigation Reform Act , Media Contact , Vice President , Chief Operating , Health Care Amp Hospitals , Medical Pharmaceuticals , Biotechnology , Conference Call Announcements ,

Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™

Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , David Szekeres , Garym Oderda , Prnewswire Heron Therapeutics Inc , European Commission , Pharmacotherapy Outcomes Research Center , Utah Medicaid Drug Regimen Review Center , Exchange Commission , European Union , Heron Therapeutics Inc , Pain Management , Safety Information , Prescribing Information , European Economic Area , Heron Therapeutics , Private Securities Litigation Reform Act , Coronavirus Disease , Media Contact , Vice President , Chief Operating , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ஐரோப்பிய தரகு , பரிமாற்றம் தரகு , ஐரோப்பிய தொழிற்சங்கம் ,

Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative Pain for up to 72 Hours

Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative Pain for up to 72 Hours
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , David Szekeres , Prnewswire Heron Therapeutics Inc , European Commission , Drug Administration , Exchange Commission , European Union , Heron Therapeutics Inc , Barry Quart , Chief Executive Officer , Safety Information , Prescribing Information , European Economic Area , Heron Therapeutics , Private Securities Litigation Reform Act , Coronavirus Disease , Media Contact , Vice President , Chief Operating Officer , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ஐரோப்பிய தரகு , பரிமாற்றம் தரகு , ஐரோப்பிய தொழிற்சங்கம் , ஹெரான் சிகிச்சை இன்க் ,

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates
News provided by
Share this article
Share this article
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and twelve months ended December 31, 2020 and highlighted recent corporate updates.
Recent Corporate Updates
Pain Management Franchise
New Drug Application Resubmission for HTX-011 Under Review: The New Drug Application (NDA) resubmission for HTX-011, an investigational agent for the management of postoperative pain, submitted November 12, 2020 to the U.S. Food and Drug Administration (FDA), continues under review. The FDA set a Prescription Drug User Fe ....

United Kingdom , David Szekeres , Heron Biochronomer , Prnewswire Heron Therapeutics Inc , European Commission , Drug Administration , European Commission Authorization , Exchange Commission , European Union , Health Canada , Heron Therapeutics Inc , Drug Application Resubmission , New Drug Application , Prescription Drug User Fee Act , Commission Authorization , Postoperative Pain , Greater Pain Reduction Compared , Current Standard Of Care , Bunionectomy Study , Product Sales , Net Product Sales , Product Sales Guidance , Approved Oral Aprepitant , Investigational New Drug , Barry Quart , Chief Executive Officer ,